EP4065072A1 - Utilisation des hydroperoxyalcools et de leurs dérivés comme agents antimicrobiens - Google Patents
Utilisation des hydroperoxyalcools et de leurs dérivés comme agents antimicrobiensInfo
- Publication number
- EP4065072A1 EP4065072A1 EP20828300.2A EP20828300A EP4065072A1 EP 4065072 A1 EP4065072 A1 EP 4065072A1 EP 20828300 A EP20828300 A EP 20828300A EP 4065072 A1 EP4065072 A1 EP 4065072A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- group
- compound
- hydroperoxyalcohol
- skin
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/38—Percompounds, e.g. peracids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/006—Antidandruff preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/02—Preparations for cleaning the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/524—Preservatives
Definitions
- hydroperoxyalcohols and their derivatives as antimicrobial agents
- the invention relates to the use of a compound of hydroperoxyalcohol type, or a 1,2,4-trioxane thereof, as an antimicrobial agent, making it possible to envisage its use in various applications and in particular as a preservative and / or. to improve the antimicrobial properties of at least one preservative, to modulate the skin microbiota, in the treatment or prevention of a disease of the skin, mucous membrane and / or integuments or even to sanitize, sanitize, disinfect and / or sterilize a surface other than the skin, integuments and mucous membranes, in particular a hard surface or a textile. It also relates to a composition, in particular cosmetic or dermatological, comprising such a compound.
- the ozonides vegetable oils are known since the early 20th century.
- the first processes used oxygen (US 984,722) then since the mid-1980s, the processes are based on ozone (US 4,591, 602), this gas making it possible to obtain a higher peroxide number and which gives thus with ozonated oils obtained with antibacterial, antifungal, antiviral, anti-inflammatory, analgesic and immunomodulatory properties, in particular for infections of the skin and mucous membranes (Koech, Afr. J. Health Sci. 2008, 15, 1).
- ozonated oils often have a reputation for emitting an unpleasant ozone odor.
- Benzoyl peroxide is widely used in the treatment of acne, but this product has the disadvantage of being irritating to the skin.
- These compounds can be used either as preservatives in various types of products, in particular cosmetic products, or as antimicrobial disinfectants, or even to modulate the skin microbiota.
- the skin microbiota is made up of around 1 million germs per cm 2 and is therefore made up of several hundred distinct species, including bacteria, fungi, parasites and viruses. It includes in particular the transient flora formed of microorganisms that are found more or less durably on the skin, depending on the environmental conditions (humidity, pH, temperature) and the state of health of the subject. These microorganisms are generally harmless, but some can cause disease. Their development is blocked by the microorganisms of the commensal flora (or resident flora) which inhabit the horny layer and the superficial layer of the epidermis and which live at the expense of their host without causing damage.
- the commensal flora forms a unique and complex balance, one of the main functions of which is the body's defense against pathogenic microorganisms.
- Staphylococcus epidermidis 5 (Gram +) is one of the most abundant bacteria in the skin microbiota, which helps the skin to synthesize antimicrobial peptides interfering with colonization of the skin by Staphylococcus aureus (Gram +), which is a common pathogen.
- Microorganisms can be classified according to the two types of flora.
- the microorganisms of the commensal flora are for example the Propionibacteriaceae (in particular Cutibacterium acnes, P granulosum and P avidum), the Staphylococcaceae (for example S epidermidis, S hominis, S hameolyticus, S aureus and S simulans), Micrococcaceae, Corynebacteriaceae (for example C. xerosis, C. jeikeium and C.
- the microorganisms of the transient flora are, for example, Staphylococcaceae (S aureus), Streptococcus, Enterobacteriaceae, Pseudomonadaceae, Bacillaceae of the genus Bacillus (for example B neisseria), and yeasts of the Candida type (in particular C albicans and C parapsiloopsis).
- the skin microbiota which is specific to each individual, can be subject to multifactorial variations, depending in particular on the area of the skin concerned (armpits, navel, soles of the feet, scalp, back, etc.), physical characteristics. chemical (humidity, salinity, temperature, pH, sweat, sebum), endogenous characteristics (subject's sex, age, genetic factors) and exogenous characteristics (use of cosmetics and hygiene products, lifestyle, exposure to the sun, environment). It forms a symbiosis with the skin. Maintaining the balance of the skin microbiota is essential for preserving the protective functions of the skin. When there is an imbalance, or dysbiosis, skin disorders can appear. The regulation of the skin microbiota makes it possible in particular to strengthen the barrier function of the skin, including the scalp, and thus improve its hydration, reduce skin irritation and the formation of scales and dandruff.
- hydroperoxyalcohols or beta-hydroxy hydroperoxides
- 1,2,4-trioxanes obtained from the latter
- these compounds could be prepared from mono- or polyunsaturated olefins according to a green, simple and efficient process. In particular, this process does not use ozone, which remains a dangerous and toxic gas, and the use of which must be perfectly supervised.
- the invention relates to the use of a hydroperoxyalcohol type compound, or a 1,2,4-trioxane thereof, as a preservative and / or to improve the antimicrobial properties of at least one preservative.
- It also relates to the cosmetic use of a compound of hydroperoxyalcohol type, or a 1,2,4-trioxane thereof, to modulate the skin microbiota.
- hydroperoxyalcohol-type compound or a 1,2,4-trioxane thereof, for its use as an antimicrobial agent in the treatment or prevention of a disease of the skin, mucosa and / or skin. dander of a human or animal subject. It also relates to the use of a compound of hydroperoxyalcohol type, or a 1, 2,4-trioxane thereof, as an antimicrobial agent for sanitizing, sanitizing, disinfecting and / or sterilizing a surface other than the skin, the appendages. and mucous membranes, in particular a hard surface or a textile.
- compositions containing an effective amount of at least one compound of hydroperoxyalcohol type, or a 1,2,4-trioxane thereof, and at least one excipient chosen from surfactants, thickeners. , pigments, dyes, perfumes and their mixtures, in particular a cosmetic or dermatological composition further comprising a physiologically acceptable medium optionally containing water.
- Figure 1 shows the antibacterial activity of oleic acid hydroperoxyalcohol on different bacterial strains.
- halogen is meant fluorine, chlorine, bromine or iodine.
- alkyl is meant a saturated or unsaturated, linear or branched aliphatic hydrocarbon group.
- a “C1-C8 alkyl” has 1 to 8 carbon atoms. Examples of alkyl (or alkyl in C1-C8) are in particular a methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, tert-butyl, pentyl, hexyl, heptyl or octyl.
- aryl is meant a 6 to 20 membered mono- or polycyclic carbocycbic group containing conjugated double bonds.
- aryl groups are phenyl, biphenyl, 1-naphthyl and 2-naphthyl, without this list being limiting.
- carrier is understood to mean an optionally unsaturated, ahphatic or aromatic mono- or polycyclic hydrocarbon-based group containing from 5 to 20 carbon atoms.
- hydroperoxyalcohol or “compound of hydroperoxyalcohol type” is meant a linear or branched, cyclic or acyclic hydrocarbon chain, comprising at least one unit:
- Said hydroperoxyalcohol can be functionalized or non-functionalized.
- the hydroperoxyalcohol carries at least one, and generally from one to four, functional group (s) inert (s) under the conditions of the hydroperoxyalcohol decomposition reaction, in particular chosen from: a carboxyl group (- COOH), an alkoxycarbonyl group (-OCOR), a hydroxyl group (-OH), a nitro group (- NO2), a halogen atom (in particular -Cl or -F ), an alkoxy group (-OR), an alkylcarbonyl group (-COR), an amido group (-CONH2, -CONHR or -CONR2) or amino (-NH2, - NHR or -NR2) and a nitrile group (-CN ), where R denotes a hydrocarbon group (for example, an alkyl or an aryl) containing from one to eight carbon atoms.
- a carboxyl group - COOH
- an alkoxycarbonyl group -OCOR
- a hydroxyl group
- the compound of hydroperoxyalcohol type is of formula (Ia) and / or (Ib): in which :
- R 1 , R 2 R 3 and R 4 each independently represent a hydrogen atom or a saturated, monounsaturated or polyunsaturated alkyl or aryl group, optionally substituted, containing from 1 to 30 carbon atoms or a group -LA where L is a bond or a linear or branched alkylene chain, containing from 1 to 30 carbon atoms, optionally substituted, and A represents a hydrogen atom or a group -COXR 'in which X denotes an oxygen atom or a group -NR ", and R' and R" each independently denote a group chosen from: a hydrogen atom, a group C1-C8 alkyl, a C4-C8 aryl group or a group - (CH2) -CH (OCOR 5 ) -CHOCOR 6 , R 5 and R 6 each independently denoting an optionally substituted linear or branched C8-C22 alkyl group and / or interrupted by at least one hydroperoxy and
- 1,2,4-trioxane is meant a compound of hydroperoxyalcohol type as defined above, in which the -OH and / or -O-OH functions of the hydroperoxyalcohol unit are substituted by a common hydrocarbon group, thus forming the following cyclic structure:
- said 1,2,4-trioxane is of formula (Ha) and / or (Ilb): in which :
- R 1 , R 2 R 3 and R 4 each independently represent a hydrogen atom or a saturated, monounsaturated or polyunsaturated alkyl or aryl group, optionally substituted, containing from 1 to 30 carbon atoms or a group -LA where L is a bond or a linear or branched alkylene chain, containing from 1 to 30 carbon atoms, optionally substituted, and A represents a hydrogen atom or a group -COXR 'in which X denotes an oxygen atom or a group -NR " , and R 'and R "each independently denote a group selected from: a hydrogen atom, a C1-C8 alkyl group, a C4-C8 aryl group or a group - (CH2) -CH (OCOR 5 ) -CHOCOR 6 , R 5 and R 6 each independently designating a linear or branched C8-C22 alkyl group optionally substituted and / or interrupted by at least one hydroper
- R 7 represents a hydrogen atom or a saturated, monounsaturated or polyunsaturated alkyl or aryl group, optionally substituted, containing from 1 to 30 carbon atoms.
- R 1 , R 2 , R 3 , R 4 in the compound of formula (la), (Ib), (Ha) and / or (Ilb) each independently represent a hydrogen atom or a optionally substituted alkyl or aryl group containing from 1 to 30 carbon atoms.
- the total number of carbon atoms in R 1 , R 2 , R 3 and R 4 is at least four, more preferably at least 10, or even at least 14. It is further preferred that 'at least one of R 3 and R 4 in the compound of formula (Ia), (Ib), (IIa) and / or (IIb) represents a hydrogen atom.
- the alkyl group when it is substituted, in the compound of formula (Ia), (Ib), (IIa) and / or (Rb), can in particular have at least one (for example, one to four) substituent (s ) chosen from a carboxyl group (-COOH), an alkoxycarbonyl group (-OCOR), a hydroxyl group (-OH), a nitro group (-NO2), a halogen atom (in particular -Cl or -F ), an alkoxy group (-OR), an alkylcarbonyl group (-COR), an amido group (-CONH2, -CONHR or -CONR2) or amino (NH2, -NHR or -NR2) and a nitrile group (-CN) , where R denotes a hydrocarbon group (eg, alkyl or aryl) containing from one to eight carbon atoms.
- substituent s
- R denotes a hydrocarbon group (eg, alkyl or aryl
- the hydroperoxy alcohol used according to the invention can be obtained:
- said hydroperoxyalcohol is obtained by a perhydrolysis process, comprising a step of perhydrolysis of the corresponding epoxide by reaction of the epoxide with an aqueous solution of hydrogen peroxide, in the presence of a catalyst consisting of phosphotungstic acid.
- the hydrogen peroxide solution is advantageously concentrated to at least 30%, or even at least 45%, and at most 60%, or even 70%, for example at 30%, 45%, 60%. or 70% (m / V).
- the hydrogen peroxide is usually used in an amount ranging from 1 to 1.5 molar equivalents, preferably in an amount of 1.1 to 1.3 molar equivalents, relative to the epoxide.
- the catalyst consisting of phosphotungstic acid is generally used in an amount ranging from 0.01 to 2% by weight, for example at least 0.1% by weight or d 'at least 0.2% by weight, in particular at least 0.4% by weight or at least 0.5% by weight, and for example at most 1.5% by weight, in particular of at most 1% by weight, based on the weight of epoxy.
- the amount of catalyst consisting of phosphotungstic acid used also represents at least 10 molar ppm, for example at least 50 molar ppm or even at least 100 molar ppm, in particular at least 200 molar ppm, or even at least 400 molar ppm or even at least 800 molar ppm and at most 2000 molar ppm, advantageously at most 1500 molar ppm, or even at most 1000 molar ppm, relative to the molar amount of epoxide.
- the perhydrolysis reaction can be carried out at a temperature of 5 to 60 ° C, preferably 20 to 60 ° C, and more preferably 30 to 50 ° C, for a period ranging from 10 minutes to 4 hours, preferably of 45 minutes to 2h30. It was observed that the catalyst consisting of phosphotungstic acid made it possible to achieve an epoxide conversion rate of at least 90%, preferably at least 95%, or even at least 99%, after this. time (as measured by 1 H NMR). The duration of the perhydrolysis reaction is all the shorter as the temperature is high, within the aforementioned ranges.
- the aforementioned reagents epoxide, hydrogen peroxide and catalyst consisting of phosphotungstic acid
- the perhydrolysis reaction be carried out in the absence of an organic solvent, that is to say of a compound capable of dissolving the epoxide and / or the catalyst and whose structure contains one or more atoms. of carbon.
- organic solvent examples include practical polar solvents such as alcohols. It was indeed demonstrated that these solvents slow down the perhydrolysis reaction at room temperature and generally decrease the yield of hydroperoxyalcohol.
- the perhydrolysis process makes it possible to obtain the desired hydroperoxyalcohol with a yield of at least 70%, generally at least 80%, or even at least 85% or even at least 90%.
- the catalytic constant (TON) of the reaction is moreover always greater than 700 and can go up to more than 15,000.
- the epoxide itself can be obtained by epoxidation of the corresponding alkene.
- the epoxidation can be carried out in a conventional manner for those skilled in the art, for example by means of a percarboxylic acid, in particular of performic acid, as described for example in document JP2015-083638.
- hydroperoxyalcohol can be obtained directly from the corresponding alkene.
- Conditions for the implementation of such a method are described in particular in patent application JP 2003/342255.
- said compound of hydroperoxyalcohol type or a 1,2,4-trioxane thereof is formed from an alkene (via an epoxide or not), said alkene being chosen from at least one acid. mono- or polyunsaturated fatty acid or its ester or mixtures thereof, in particular at least one alkyl ester of said fatty acid or at least one glyceride of said fatty acid, or a terpene.
- Examples of mono- or polyunsaturated fatty acids are in particular palmitoleic acid, oleic acid, erucic acid, ricinoleic acid or nervonic acid.
- the fatty acid or its glyceride can itself be obtained from a vegetable oil, and the fatty acid alkyl ester can be obtained by transesterification of at least one vegetable oil.
- vegetable oils mention may in particular be made of wheat germ, sunflower, argan, hibiscus, coriander, grape seed, sesame, corn, apricot and castor oil, shea, avocado, olive, soybean, sweet almond, palm, rapeseed, cottonseed, hazelnut, macadamia, jojoba, alfalfa, poppy, pumpkin, sesame, squash, blackcurrant, evening primrose, lavender, borage, millet, barley, quinoa, rye, safflower,nadooulier, passionflower, musk rose, Echium, camelina or camellia.
- the compound of hydroperoxyalcohol type is obtained by perhydrolysis of an epoxidized vegetable oil, advantageously chosen from those listed above, preferably olive oil.
- Terpenes include in particular monoterpenes, sesquiterpenes, diterpenes, sesterpenes, triterpenes, carotenoids or even terpenoids, preferably sesquiterpenes or carotenoids.
- terpenes are in particular ⁇ ' ⁇ -pinene, ⁇ -pinene, carene, limonene, a carotene, ocimene, myrcene, citronellene, methoxycitronellene, famesene, squalene, astaxanthin, without this list is not exhaustive.
- alkenes are in particular dodecene, tridecene, cycloheptene, cyclooctene, or cycloocta-1, 5-diene, without this list being exhaustive.
- 1,2,4-trioxane can be prepared by reacting a hydroperoxyalcohol with an aldehyde or a ketone, generally in the presence of a Brpnsted or Lewis acid catalyst. Such a method is described in particular in the article Griesbeck et al. Or g. Lett. 2002, 4, 24, 4193-4195.
- the compounds described above have proved to be effective as antimicrobial agents, which makes it possible to envisage their use as preservatives, or as cosmetic or dermatological active agents, or even as disinfecting agents, depending on the dose used that a person skilled in the art can easily. determine.
- a first object of the invention thus relates to the use of a compound of hydroperoxyalcohol type, or a 1,2,4-trioxane thereof, as a preservative and / or for improving the antimicrobial properties of at least one preservative. .
- the compound according to the invention can be formulated in any type of composition, in particular cosmetic, dermatological or detergent, in particular in the form of an oily composition or of an emulsion.
- this composition can be applied to any type of substrate, in particular to the skin, integuments and in particular to the hair or the eyelashes, or else to hard surfaces or textiles.
- preservatives are 1,2-C5-C10 alkanediols such as 1,3-propanediol, pentylene glycol, hexanediol, octanediol (or caprylyl glycol) and decanediol; glycerol and C3-C8 alkyl ethers such as octoxyglycerin; rhinokitiol; benzoic acid; sorbic acid; potassium sorbate; dehydroacetic acid; phenoxyethanol; parabens; and their mixtures.
- 1,2-C5-C10 alkanediols such as 1,3-propanediol, pentylene glycol, hexanediol, octanediol (or caprylyl glycol) and decanediol
- glycerol and C3-C8 alkyl ethers such as octoxyglycerin
- the aforementioned composition contains from 0.001 to 1%, preferably from 0.01% to 0.1%, of hydroperoxyalcohol type compound, or a 1,2,4- trioxane thereof.
- Another object of the invention relates to the cosmetic use of a compound of hydroperoxyalcohol type, or a 1,2,4-trioxane thereof, for modulating the skin microbiota and thus preventing and / or reducing the unsightly manifestations of alteration of the skin's microbiota, including the scalp.
- cosmetic use is meant a non-therapeutic use on healthy skin.
- modulating the skin microbiota is meant to prevent and / or treat an imbalance of the skin microbiota which may be due to one or more extrinsic factors such as environmental factors (temperature, ambient humidity, pollution, UV), drug treatments ( antibiotic, corticosteroid), or the application to the skin of hygiene products (in particular containing fatty acid soaps), detergents or antiperspirants.
- the modulation of the skin microbiota more particularly comprises the modification of the relative proportion of the microorganisms present on the surface of the skin, possibly including the scalp.
- Modulation of the skin microbiota makes it possible in particular to prevent or reduce at least one unsightly manifestation of the imbalance of the skin microbiota such as the formation of dandruff and / or scales (resulting in particular from an imbalance between bacteria and fungi of the genus Malassezia ), the formation of blackheads, roughness of the skin, inhomogeneity of the complexion, the development of odors (formed in particular by reaction of S hominis with sebum), and / or hair loss.
- the imbalance of the skin microbiota such as the formation of dandruff and / or scales (resulting in particular from an imbalance between bacteria and fungi of the genus Malassezia ), the formation of blackheads, roughness of the skin, inhomogeneity of the complexion, the development of odors (formed in particular by reaction of S hominis with sebum), and / or hair loss.
- the hydroperoxyalcohol-like compound, or a 1,2,4-trioxane thereof be included in a composition.
- cosmetic containing 0.001 to 15%, preferably 0.01% to 10%, for example 0.1 to 5% by weight, of this compound.
- This cosmetic composition comprises a cosmetically acceptable medium, that is to say suitable for topical application to the skin (including the scalp), the mucous membranes, and / or integuments and which does not generate redness, tingling or other unpleasant manifestations incompatible with cosmetic application. It is in particular in the form of an oily composition or an emulsion, more particularly a water-in-oil or oil-in-water emulsion.
- the composition may have a more or less fluid texture and may be in the form of an oily solution or dispersion, a fluid, a cream, a balm or a solid composition of the bread type. It can be packaged in a pump-bottle, tube, jar or aerosol device.
- the cosmetic composition can, for example, be used as a composition for itself, for cleansing and / or making up the skin, or alternatively as a shampoo or conditioner.
- Another object of the invention relates to a hydroperoxyalcohol-type compound, or a 1,2,4-trioxane thereof, for its use as an antimicrobial agent, in the treatment or prevention of a disease of the skin, of the mucous membrane and / or integuments of a human or animal subject.
- an antimicrobial agent is meant a substance that kills, slows the growth or blocks the growth of one or more microbes.
- growth denotes, in the present invention, any cellular operation allowing a volumetric increase of the cell, a cell division or a cell reproduction.
- a microbe designates according to the present invention any unicellular or multicellular organism pathogenic or parasitic of other living organisms such as humans or animals. Among the microbes, mention may in particular be made of molds, fungi, yeasts, bacteria and viruses.
- An antimicrobial agent according to the present invention can for example be an antibiotic, antiviral, antifungal and / or antibacterial agent.
- antifungal in particular fungicide, and / or fungistatic.
- antibacterial in particular bactericidal and / or bacteriostatic.
- fungicidal or fungistatic agent is meant an agent capable respectively of eliminating at least one type of mold, fungus or yeast, or of slowing down the development of at least one type of mold, fungus or yeast.
- bactericidal or bacteriostatic agent an agent capable respectively of eliminating at least one type of bacteria or of slowing down the development of at least one type of bacteria.
- bacterium By bacterium is meant eubacteria and archaeobacteria.
- Eubacteria include fermicutes, gracilicutes, and temicutes.
- Gracilicutes include Gram negative bacteria such as Enterobacteriaceae, such as Klebsellia (such as Klebsellia pneumoniae) and Escherichia (such as Escherichia coli).
- Fermicutes include Gram positive bacteria, such as Micrococcaceae, such as for example Staphylococci (such as Staphylococcus aureus) and stems forming endospores including bacilli (Bacillaceae) such as for example Bacillus circulans.
- the bacteria are chosen from: Propioni bacteri aceae (in particular Cutibacterium acnes, P granulosum and P avidum), Staphylococcaceae (for example S epidermidis, S hominis, S hameolyticus, S aureus and S simulans), Micrococcaceae , Corynebacteriaceae (for example C.
- molds denotes in particular fungi and yeasts, preferably of the genus Malassezia, in particular M globosa and M restricta, or of the genus Candida, in particular C albicans and C parapsiloopsis, or of the genus Aspergillis such as Aspergillus niger or of the genus
- said antimicrobial agent is an antibacterial agent.
- diseases of the skin, mucosa and / or integuments include acne, herpes, yeast infection, athlete's foot, chickenpox, wart, shingles , psoriasis, conjunctivitis, stye, eczema, vitiligo, atopic dermatitis or keratosis, preferably acne.
- An example of a skin disease of an animal subject is ringworm.
- treatment of a disease (or disorder, or condition) includes alleviation of at least one symptom thereof, reduction in its severity, delay or inhibition.
- Treatment does not necessarily mean that the disease (or, disorder or condition) is completely cured.
- a compound used according to the present invention can, in some cases, only reduce the severity of a disease (or disorder, or condition), reduce the severity of symptoms associated with it, improve a patient's quality of life or a subject, or delay or inhibit the onset of a disease (or disorder, or condition).
- prevention refers to any reduction, however slight, in the predisposition or risk of developing a condition, disease, disorder or symptom thereof.
- the subject can be any subject and, preferably, is a subject who is at risk of developing or is predisposed to the development of a condition, disease or disorder.
- prevention includes either the prevention of the onset of a disease, or clinically obvious disorder, or the prevention of the onset of a disease, or a preclinical disorder, in people or animals. at risk. This includes the prophylactic treatment of those at risk of developing a disease, or disorder.
- the compounds according to the invention are advantageously used as antimicrobial agents for combating bacteria of the genus Staphylococcus, Streptococcus, Corynebacterium and Propionibacterium, involved in particular in atopic dermatitis, acne and psoriasis.
- hydroperoxyalcohol type compound or a 1,2,4-trioxane thereof, is included in a composition containing 0.5 to 10%, preferably 1. % to 5%, of this compound.
- this pharmaceutical composition can be carried out orally, topically, ocular, intraocular, intravenous, parenteral, subcutaneous, epicutaneous, intradermal, transdermal, intramuscular, enteral, rectal, intranasal, sublingual, buccal, intra-respiratory or by nasal inhalation.
- the pharmaceutical composition is a dermatological composition administered topically to the skin, mucous membranes, and / or integuments.
- the hydroperoxyalcohol-like compound, or a 1,2,4-trioxane thereof can be used as an antimicrobial agent to sanitize, sanitize, disinfect and / or sterilize an inert surface, i.e. a surface other than the skin, integuments and mucous membranes, in particular a hard surface or a textile.
- the hydroperoxyalcohol used according to the invention can be included in a composition which further comprises one or more excipients.
- the composition may include, in some cases, a combination of at least one hydroperoxyalcohol type compound and at least one 1,2,4-trioxane.
- the excipient (s) of the composition can be any excipient known to a person skilled in the art and suitable for the type of application of the composition.
- excipients include sequestrants, antioxidants, preservatives, fillers, electrolytes, humectants, colorants, fragrances, essential oils, moisturizers, vitamins, essential fatty acids, surfactants and / or emulsifiers, gelling agents, thickening agents, buffering agents, lipophilic excipients, or a mixture thereof.
- excipients include sequestrants, antioxidants, preservatives, fillers, electrolytes, humectants, colorants, fragrances, essential oils, moisturizers, vitamins, essential fatty acids, surfactants and / or emulsifiers, gelling agents, thickening agents, buffering agents, lipophilic excipients, or a mixture thereof.
- a person skilled in the art will take care to choose this or these optional excipients, and / or their
- An object of the invention thus relates to a composition containing an effective amount of at least one compound of hydroperoxyalcohol type, or a 1,2,4-trioxane thereof, and at least one excipient chosen from surfactants, thickeners. , pigments, dyes, perfumes and their mixtures, in particular a cosmetic or dermatological composition further comprising a physiologically acceptable medium optionally containing water.
- the composition according to the invention can also comprise at least one active agent chosen from desquamating agents, soothing or anti-inflammatory agents, anti-seborrheic agents and their mixtures.
- the composition may comprise at least one active agent chosen from probiotics, such as a bacterium of the genus Lactobacillus or Bifidobacterium; prebiotics, such as beta-glucan, inulin, ⁇ -galactooligosaccharides and fructooligosaccharides; postbiotics, such as lactic acid and omega-3 and omega-6 polyunsaturated fatty acids; and their mixtures.
- the composition according to the invention generally comprises water and at least one surfactant chosen from anionic, cationic, amphoteric and nonionic surfactants and their mixtures.
- Example 2 Antimicrobial activity of hydroperoxyalcohol (or “HPA”) obtained from oleic acid
- a sample solution at 10,000 ppm in DMSO for a sample of HPA at 72% purity (ie 15,000 ppm of active material) was dried on an inert support. Once the solution had dried, a volume of inoculum from each bacterial strain was placed on the support in contact with the sample for 0 and 24 h at room temperature.
- a pure solution of DMSO was dried on the support under the same conditions as the samples.
- An untreated support (noted as support control in FIG. 1) was also inoculated, in order to verify the stability of the strains under the conditions of the test.
- CFU colony forming unit
- the bacterial strains targeted are: Gram -: Pseudomonas aeruginosa
- Gram + Cutibacterium acnes, Enterococcus hirae, Staphylococcus aureus
- Normal human dermal fibroblasts were cultured in the form of a monolayer in a DMEM medium (1% S VF) for 24 hours in the presence of a solution containing different concentrations of an HPA derived from olive oil.
- This HPA was prepared according to a process analogous to that described in Example 1 which was carried out on olive oil previously epoxidized in a conventional manner for those skilled in the art.
- the compound according to the invention exhibits good harmlessness to skin cells over a wide range of concentrations and can thus be used for cosmetic and dermatological applications.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Birds (AREA)
- Emergency Medicine (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1913526 | 2019-11-29 | ||
| PCT/FR2020/052212 WO2021105638A1 (fr) | 2019-11-29 | 2020-11-27 | Utilisation des hydroperoxyalcools et de leurs dérivés comme agents antimicrobiens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP4065072A1 true EP4065072A1 (fr) | 2022-10-05 |
Family
ID=73856196
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP20828300.2A Pending EP4065072A1 (fr) | 2019-11-29 | 2020-11-27 | Utilisation des hydroperoxyalcools et de leurs dérivés comme agents antimicrobiens |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230181520A1 (fr) |
| EP (1) | EP4065072A1 (fr) |
| JP (1) | JP2023504422A (fr) |
| CN (1) | CN114727929A (fr) |
| WO (1) | WO2021105638A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3123208A1 (fr) * | 2021-06-01 | 2022-12-02 | Demeta | Utilisation cosmétique d’un hydroperoxyalcool pour lutter contre les signes cutanés du vieillissement |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US984722A (en) | 1909-05-14 | 1911-02-21 | Gerard Ozone Process Company | Composition yielding ozone. |
| US4591602A (en) | 1982-04-16 | 1986-05-27 | James H. Brown | Ozonide esters and topical compositions containing same |
| FR2604435B1 (fr) * | 1986-09-30 | 1988-12-02 | Oreal | Peroxydes aromatiques insatures et leur utilisation en therapeutique et cosmetique |
| FR2704726B1 (fr) * | 1993-05-05 | 1995-06-16 | Chemoxal Sa | Composition aqueuse comportant un péroxyacide organique et ses utilisations comme agents désinfections. |
| RU2131673C1 (ru) | 1998-04-17 | 1999-06-20 | Педдер Валерий Викторович | Способ получения озонированного масла "отрисан" |
| JP2003342255A (ja) | 2002-05-24 | 2003-12-03 | Mitsui Chemicals Inc | ヒドロペルオキシヒドロキシオクタデカン酸エステル組成物、及び該組成物からの9−オキソノナン酸誘導体の製造方法 |
| ITRM20050514A1 (it) | 2005-10-17 | 2007-04-18 | Gabriele Maietta | Olio ozonizzato, principio attivo di elevata stabilita' a base di perossidi utilizzabile per applicazioni terapeutiche mediche e per trattamenti domiciliari similari a quelli dell'ozonoterapia, senza l'utilizzo di ozono gassoso. |
| ITMI20111045A1 (it) | 2011-06-10 | 2012-12-11 | Uni Del Salento | Procedimento per l'ozonizzazione di un olio vegetale. |
| JP6331331B2 (ja) | 2013-10-25 | 2018-05-30 | 横浜ゴム株式会社 | エポキシ樹脂接着剤組成物 |
| FR3093108B1 (fr) * | 2019-02-21 | 2021-03-05 | Demeta | Procédé de perhydrolyse d'époxydes aliphatiques |
-
2020
- 2020-11-27 EP EP20828300.2A patent/EP4065072A1/fr active Pending
- 2020-11-27 JP JP2022531552A patent/JP2023504422A/ja active Pending
- 2020-11-27 WO PCT/FR2020/052212 patent/WO2021105638A1/fr not_active Ceased
- 2020-11-27 CN CN202080080233.0A patent/CN114727929A/zh active Pending
- 2020-11-27 US US17/779,578 patent/US20230181520A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230181520A1 (en) | 2023-06-15 |
| WO2021105638A1 (fr) | 2021-06-03 |
| CN114727929A (zh) | 2022-07-08 |
| JP2023504422A (ja) | 2023-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2483228B1 (fr) | Utilisation de dérivés de vanilline comme conservateur, procédé de conservation, composés et composition | |
| FR2950806A1 (fr) | Composition, utilisation et procede de conservation | |
| WO2012120454A1 (fr) | Composition à base d'huile ozonisée destinée à une utilisation topique | |
| JP5681630B2 (ja) | 抗菌性ゲル製剤 | |
| EP0953345B1 (fr) | Utilisation d'au moins un hydroxystilbène en tant qu'agent diminuant l'adhésion des micro-organismes | |
| WO2018185408A1 (fr) | Ingredient protecteur de l'equilibre de la flore microbienne cutanee et/ou mucosale | |
| EP1133979B1 (fr) | Utilisation de corps gras particuliers permettant de modifier les propriétés physico-chimiques de la peau et/ou des muqueuses en tant qu'agents empêchant ou diminuant l'adhésion des micro-organismes sur ces dernières | |
| CA2408383A1 (fr) | Utilisation de l'acide ellagique comme agent cosmetique anti-pollution | |
| EP1129694B1 (fr) | Utilisation de composés permettant de modifier les propriétés physico-chimiques de la peau et/ou des muqueuses en tant qu'agents empêchant ou diminuant l'adhésion des micro-organismes sur ces dernières | |
| JP2025527220A (ja) | 殺生物性組成物 | |
| WO2021105638A1 (fr) | Utilisation des hydroperoxyalcools et de leurs dérivés comme agents antimicrobiens | |
| EP2583662B1 (fr) | Composition à base de meroterpene destinée aux peaux grasses, à tendance acneique ou atteintes d'acne | |
| KR102886232B1 (ko) | 화장품, 생활용품 및 손 세정제용 항균 조성물 | |
| FR2921560A1 (fr) | Nouvelles compositions visant a la protection microbienne et a la conservation des produits cosmetiques | |
| FR2921558A1 (fr) | Composition antimicrobienne utilisable en cosmetique et en dermatologie. | |
| WO2022129773A1 (fr) | Composition désinfectante comprenant un mélange de phénol, d'aldéhyde et d'alcool, et son utilisation pour désinfecter une surface ou en cosmétique pour désinfecter la peau, notamment les mains | |
| KR20210158255A (ko) | 곰취추출물을 유효성분으로 함유하는 광역학 반응용 조성물, 이를 포함하는 항균, 항진균 및 살균 조성물, 및 상기 광역학 반응용 조성물을 이용한 살균방법 | |
| EP3946235A1 (fr) | Utilisation de dianhydrohexitol pour éliminer les effets cosmétique de l'acné, des pellicules et des mauvaises odeurs | |
| JP2014503468A (ja) | 保存剤としての置換メトキシアルコキシフェニルアルキル誘導体の使用、保存方法、化合物、および組成物 | |
| WO2020193744A1 (fr) | Utilisation de dianhydrohexitol pour la conservation des préparations cosmétiques | |
| FR2950885A1 (fr) | Utilisation de derives de vanilline comme conservateur, procede de conservation, compose et composition. | |
| FR2939677A1 (fr) | Utilisation de derives c-glycosides comme agents anti-adhesion microbienne |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20220527 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20231221 |
|
| 19U | Interruption of proceedings before grant |
Effective date: 20230201 |